Dr. Paul Maddon

https://www.acorda.com/assets/docs/news/02-01-11-914inc.pdf.

Dr. Maddon is in the middle. Mentioned last week that Progenics and Regeneron share the same address. The gentleman to the left of Dr. Maddon is an executive with Regeneron. In fact he is Chief Science Officer of Regeneron. Speculating that he has had a chat or two with Dr. Roy Vagelos, Regeneron's COB. Vagelos is a research driven MD and he was the one who brought Mevacor, the very first statin to market from Merck. He was rewarded with the position of Merck CEO. Heck! I will go even further and suggest that Dr. Maddon and Dr. Vagelos have shared the same bar stool from time to time. Shoutout to the Stocktwits poster for the posting of this article.

Will try more fancy while I am at the speculation game. MGK, God bless him, talked about Cytodyn and Phase 2 yesterday. I proposed that Cytodyn was into Phase 2 already. I share the attitude of MGK in that Cyrus is a strategist. Propose for your entertainment that the moment the 4 Horsemen, outside experts, set the stage for the unraveling of the Amarex data, Cyrus was thinking beyond the Clinical hold. He showcased our future by turning over some of the presentation to another set of experts and making such prognostications known to the SEC by including their statements in a Governmental form. No hiding or double speak but bold clarity. Would not be surprised that Cyrus is not already deep into Phase 3.

How many times have we heard that "the trend is your friend". Just go to Linkedin and check out the trend that is the career of Cyrus. Fully expect that Cytodyn will be a footnote in BioTech history just like the Keytruda scientists who invented that drug require a Google search. It is a question of when not how for us.

​